Perth-based Orthocell Expands with New Bio-Manufacturing Facility

Australia: Perth-based regenerative medicine company, Orthocell, has unveiled its latest venture—a state-of-the-art bio-manufacturing facility in Murdoch, Perth. 

The expansion comes on the heels of Orthocell’s lucrative $23.1 million global exclusive marketing and distribution agreement with BioHorizons, one of the world’s largest dental implant companies, for its product, Striate+.

New Facility in Murdoch

The newly established facility in Murdoch boasts the capacity to manufacture up to 100,000 units of Striate+ annually, a considerable upgrade from the previous production volume of 10,000 units. Mr Anderson acknowledges the crucial role played by the bio-manufacturing facility in meeting the manufacturing requirements and demands of their partner, BioHorizons. He states, “This new bio-manufacturing facility is going to carry the bulk of the load of that new manufacturing requirements to meet our partner’s needs.”

Striate+, has achieved regulatory approval in multiple jurisdictions, including Europe, the United States, and Australia. Mr Anderson emphasizes the significance of this accomplishment, not only for the company but also for the broader Australian manufacturing landscape. 

“The fact that we’ve been able to develop a product, to have that product regulatory-approved across European, American and Australian jurisdictions…is a really major milestone for not just our company but for the Australian manufacturing environment,” said Mr Anderson. 

Global Market Challenges as an Australian-based Company

As an Australian-based company, Orthocell faces challenges in accessing global markets. Mr Anderson recognizes the potential of Australia as an ideal environment for developing cutting-edge technologies. He expresses the company’s dedication to preserving manufacturing capabilities and intellectual property within Australia. According to a press release, the establishment of the bio-manufacturing facility marks a significant step forward in strengthening Orthocell’s position in the global market.

In addition to Striate+, Orthocell is also actively developing its Remplir nerve repair device, which obtained market approval in Australia in March last year. Mr Anderson foresees the combined success of these two products as instrumental in increasing the company’s revenues and overall stability. 

Furthermore, Orthocell is keen on exploring new markets, including Brazil, Japan, and Canada, as part of its comprehensive commercialization strategy.